<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301193</url>
  </required_header>
  <id_info>
    <org_study_id>84317</org_study_id>
    <nct_id>NCT04301193</nct_id>
  </id_info>
  <brief_title>Evaluation of Novel Point of Care Coagulation System in Pregnant Women</brief_title>
  <acronym>CCPW</acronym>
  <official_title>Evaluation of Novel Point of Care Coagulation System in Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HemoSonics LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will evaluate a new point of care Quantra Hemostasis Analyzer&#xD;
      system to assess coagulation rapidly with ease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Unexpected bleeding continues to be an issue that confronts anesthesiologists. Obstetric&#xD;
      bleeding spearheads as the leading cause of maternal mortality and morbidity. One of the&#xD;
      hurdles that clinicians confront is a lack of point of care coagulation system that can&#xD;
      hasten the clinical management strategy in the right direction. Conventional methods take&#xD;
      considerable time to obtain results. TEG and ROTEM are currently doing the job however these&#xD;
      two modalities requires expertise and proficient training to perform test and interpret&#xD;
      results. The level of expertise to run the TEG and ROTEM poses hurdles for providing&#xD;
      coagulation around the clock as it requires trained operators. What is currently required for&#xD;
      efficient and effective management of obstetric hemorrhage is a point of care coagulation&#xD;
      system in the operating room and or labor and delivery suite that is user friendly, easy and&#xD;
      quick to perform. In this study the investigators will evaluate a new point of care Quantra&#xD;
      Hemostasis Analyzer system to assess coagulation rapidly with ease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of coagulation using Quantra system.</measure>
    <time_frame>Baseline</time_frame>
    <description>How Fibrinogen level of the patient is reflected by FCS (Fibrinogen Clot Strength of Quantra)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine how other conventional tests such as PT, PTT, and INR relate to clotting time of Quantra.</measure>
    <time_frame>Baseline</time_frame>
    <description>How PT, PTT, and INR level of the patient is reflected by Clot Strength of Quantra</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hemorrhage</condition>
  <condition>Coagulation Delay</condition>
  <arm_group>
    <arm_group_label>Pregnant Women</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects will have the same intervention. Samples will be taken and manipulated in the laboratory for use of the Hemosonic Qauntra Analyzer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Quantra Analyzer</intervention_name>
    <description>Subjects blood will be manipulated in the lab and will be tested with the Quantra Analyzer</description>
    <arm_group_label>Pregnant Women</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman at 37-41 weeks gestation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Preeclampsia&#xD;
&#xD;
          -  Gestational diabetes&#xD;
&#xD;
          -  Preexisting coagulopathy&#xD;
&#xD;
          -  History of deep vein thrombosis (DVT)&#xD;
&#xD;
          -  Medications that impair coagulation&#xD;
&#xD;
          -  History of pulmonary embolism or thrombosis&#xD;
&#xD;
          -  Women in active labor receiving intravenous fluids or oxytocin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhavani Kodali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Bhavani Kodali</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 2, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT04301193/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

